Eosinophil-derived COX-2 protects against experimental colitis by enhancing IL-22 production via PGE2.

Inflammatory bowel disease (IBD), encompassing conditions like Crohn's disease and ulcerative colitis, remains a significant global health challenge with limited curative options. Current therapies often target broad immune suppression, leading to side effects and incomplete remission. Eosinophils, traditionally associated with allergic responses, are increasingly recognized for diverse roles in tissue homeostasis and inflammation. Understanding their specific contributions, particularly in gut immunity, could unlock novel therapeutic pathways. This study delves into the protective role of eosinophil-specific COX-2 in colitis, addressing a critical gap in our knowledge of immune cell-mediated gut protection.

Researchers investigated the role of eosinophil-derived COX-2 in experimental colitis using genetically modified mice. They utilized Ptgs2fl/fleoCre+/- mice, which specifically lack COX-2 (encoded by Ptgs2) in eosinophils, to model the impact of this enzyme deficiency. The study assessed colonic inflammation and various immunological parameters in these mice compared to controls. Furthermore, they explored the therapeutic potential of PGE2 analog treatment to restore protective mechanisms, specifically evaluating its effect on IL-22 production and mucosal integrity in the context of COX-2 deficiency.

The study revealed that eosinophil-derived COX-2 plays a crucial protective role against experimental colitis. Mechanistically, COX-2 enhanced IL-22 production by type 3 Innate Lymphoid Cells (ILC3s) through prostaglandin E2 (PGE2) signaling. This finding establishes a direct link between eosinophil activity and a key cytokine in gut barrier function. Consistently, Ptgs2fl/fleoCre+/- mice, lacking eosinophil COX-2, exhibited reduced colonic PGE2 levels. This deficiency led to compromised mucosal protection. Importantly, PGE2 analog treatment successfully restored IL-22 production and the protective mucosal barrier in these COX-2-deficient mice. The researchers also observed that eosinophil COX-2 enhanced mitochondrial function in both the colon and immune cells. This metabolic improvement was coupled with beneficial changes in the gut microbiota: > The study found higher levels of the beneficial bacteria Lactobacillus reuteri and Akkermansia muciniphila in the intestine when eosinophil COX-2 was present. These combined effects—enhanced IL-22, improved mitochondrial function, and a healthier gut microbiome—collectively contributed to alleviating colitis and protecting against intestinal damage.